申请人:AnTolRx, Inc.
公开号:US20220387398A1
公开(公告)日:2022-12-08
The present invention features agents for treating autoimmune diseases and other conditions characterized by pathological immune responses, and for preventing or reversing immune recognition of neoantigens associated with therapeutic proteins or gene therapy vectors.